Ajanta Pharma

Last updated

Ajanta Pharma Limited
Company typePublic Company
Industry Pharmaceuticals, Drugs & Healthcare
Founded1973 , 51 years
Headquarters
Mumbai, Maharashtra [1]
,
India
Key people
Yogesh Agrawal, Managing Director. Rajesh Agrawal, Joint Managing Director
ProductsBranded Generic Formulations / Medicines
RevenueIncrease2.svg₹2,916 crore (US$350 million) (2020–2021)
Number of employees
7,000+
Subsidiaries
  • Ajanta Pharma (Mauritius) Ltd
  • Ajanta Pharma Philippines Inc.
  • Ajanta Pharma USA Inc. [2]
  • Ajanta Pharma Nigeria Ltd. [3]
Website http://www.ajantapharma.com/
Footnotes /references
; [1] [2] [3]

Ajanta Pharma Limited, also known by the acronym APL, is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, South East Asia, West Asia, and CIS. It was established in 1973.

Contents

Markets and business

Ajanta Pharma has over 1,400 products registered currently in various countries and an equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management.

Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management.

Ajanta Pharma has recently stepped up its presence in the United States with a select product portfolio, which includes niche and complex technology products. Currently, the company has 27 products in the US market. [4]

History

In the early 2000s, Ajanta was noted as a major source of foreign currency, alongside Reddy Labs, arising from sales in Southeast Asia. [5] In particular, in 2003, a joint-venture between Ajanta and the Ministry of Health in Turkmenistan accounted for fully half of the pharmaceutical needs of the country. [5] The company had made several other joint-ventures with regional governments, such as Uzbekistan, Kazakhstan, Kyrygyzstan and Tajikistan, which it severed in the 2010s due to their being unprofitable. [6]

The company experienced an enormous loss in 2005 [nt 1] in terms of diminution of the value of investments, amounting to four times the year's profits. [7] That same year, the company was noted as having the highest sales in India for any Indian pharmaceutical company, with sales of ₹13.56 billion. [8]

In 2015, the company was highlighted as having had exceptional stock appreciation over the preceding four years, and the listing of the stock on the BSE 500 was noted. [9] By 2019, the stock was listed on the S&P BSE 200 index. [10]

Manufacturing facilities

Ajanta Pharma operates seven manufacturing facilities in India. Six facilities manufacture finished formulations, including Dahej and Paithan plants which is approved by the US FDA and Guwahati plant which caters to domestic and emerging markets. Another plant manufactures active pharmaceutical ingredients (APIs) primarily for captive consumption.

Bayer [nt 2] filed suit before the Delhi High Court accusing Ajanta of patent infringement on the erectile dysfunction treatments vardenafil and vardenafil hydrochloride. [11] Ajanta argued that Bayer was not using its patent in India for the benefit of India, which led the court to provide partial relief to an injunction granted to Bayer, allowing Ajanta to manufacture but not sell the product, in January 2017. [11] Bayer and Ajanta reached an unspecified agreement after mediation was ordered by the court in February 2017. [11]

Related Research Articles

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Rohto Pharmaceutical</span> Japanese consumer goods company

Rohto Pharmaceutical Co., Ltd. is a multinational corporation in fast-moving consumer goods and pharmaceutical corporation headquartered in Ikuno-ku, Osaka, Japan. with revenues steadily increasing from ¥95,619 million in 2006 to ¥120,292 million in 2011. Skin care contributes to 61.3% of the revenues, while Eye Care contributes to 21% of their sales.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

<span class="mw-page-title-main">Amcinonide</span> Chemical compound

Amcinonide is a topical glucocorticoid used to treat itching, redness and swelling associated with several dermatologic conditions such as atopic dermatitis and allergic contact dermatitis. Amcinonide can also be classified as a multi-functional small molecule corticosteroid, which has been approved by the FDA and is currently marketed as an ointment, lotion, or cream. It acts as both a transcription factor for responses to glucocorticoids and modulator for other transcription factors while also regulating phospholipase A2 activity.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Vivimed Labs</span>

Vivimed Labs Limited is an India-based global supplier of specialty chemicals and pharmaceuticals. Headquartered in Hyderabad, India. Vivimed is a manufacturer of active pharmaceutical ingredients, active ingredients for home and personal care, hair dyes, imaging chemicals and photochromics.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

Unichem Laboratories is an Indian pharmaceutical company, headquartered in Mumbai. It manufactures and markets pharmaceutical formulations across the globe, including the regulated markets of the USA and Europe.

<span class="mw-page-title-main">Elder Pharmaceuticals</span> Indian pharmaceutical company

Elder Pharmaceuticals Ltd is a pharmaceutical company headquartered in Mumbai, Maharashtra. Its main activities include the manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices. Its largest presence in three therapeutic segments, Women's Healthcare, Wound Care and Nutraceuticals. It has 6 manufacturing plants in India & 1 in Nepal. It manufacture various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.

The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of APIs locally produced. Pakistani pharmaceutical companies are engaged in importing raw materials, compounding APIs with excipients, coating of pills, and fill-finish activities. The industry is regulated by the Drug Regulatory Authority of Pakistan, which oversees drug approvals and pricing.

Dishman Carbogen Amcis Ltd is an Indian multinational pharmaceutical company specialized in the manufacture of active ingredients and contract development and manufacturing. Dishman employs over 1,000 people worldwide and is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).

<span class="mw-page-title-main">Taro Pharmaceuticals</span> Generic pharmaceutical company

Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer that was publicly listed in the New York Stock Exchange before it was acquired by Sun Pharma. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. The company's products are mainly sold in the United States, Canada and Israel.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

References

  1. 1 2 "Welcome To Ajanta Pharma". Ajantapharma.com. Retrieved 29 February 2016.[ self-published source ]
  2. 1 2 "Stock Snippets". Daily Market Insights. TriFid Research. 15 June 2016. p. 2 – via Internet Archive. Ajanta Pharma announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.
  3. 1 2 "Ajanta Pharma Limited - Our Business". Company. Retrieved 29 February 2016.[ self-published source ]
  4. ↑ "Profit After Tax at 14% of Revenue (3rd Quarter & 9 Months, FY 2019 Consolidated Results)" (PDF) (Press release). Ajanta Pharma Limited. Archived from the original (PDF) on 27 September 2020.
  5. 1 2 Lal, Rollie (2006). Central Asia and Its Asian Neighbors: Security and Commerce at the Crossroads. United States: Project Air Force (Rand). pp. 32–3. ISBN   0-8330-3878-8 – via Google Books (Preview).
  6. ↑ GOI Considering Russian Thrust in Central Asia (Partial extract from original diplomatic, classified cable). United States Department of State. 26 September 2015. p. 2. Retrieved 8 December 2019– via Internet Archive.
  7. ↑ "Investments". Accounting & Analysis: The Indian Experience (Professional ed.). Global Data Services of India (CRISIL). 2006. p. 153. ISBN   9788190342704 – via Google Books (Preview).
  8. ↑ Thukral, R. K., ed. (2016). India Top 10 Year Book 2016. New Delhi, India: Publication Cell (Datanet India). p. 85. ISBN   978-93-80590-60-8 – via Google Books (Preview).
  9. ↑ Oberoi, Rahul (April 2015). "Bullish Moves: We discuss three ratios that can help identify good stocks". Money Today. Vol. 10, no. 4. New Delhi, India: India Today Group. p. 49 – via Internet Archive.
  10. ↑ "Ajanta Pharma Ltd Live Stock Price , Ajantpharm Live Share Price, 532331". BSE. 8 December 2019. Archived from the original on 9 December 2019. Retrieved 8 December 2019.
  11. 1 2 3 Kleyn, Madelein; van Wyk, Louis, eds. (2019). International Pharmaceutical Law and Practice. LexisNexis. pp. §14.09[11]. ISBN   9781579114725 – via Google Books (Preview).

Notes

  1. ↑ Year ending 31 March 2005
  2. ↑ Specifically Bayer Intellectual Property GMBH

Patent applications in India

Products subject to price control in India

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.